title: [An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].
abstract: A 54-year-old male had huge pre-sacral recurrent mass (54 × 41 mm) at the level of S1 sacral bone six months after he underwent a high anterior resection for advanced rectal cancer. He was considered inoperable although he had no distant metastasis. We planned a surgical resection for the recurrent tumor after the chemo-radiation therapy (radiation + CPT-11, UFT, Leucovorin). The tumor had a good response (33 × 29 mm) for CRT allowing a dissection area between sacral bone and posterior tumor margin. The surgical resection was performed. We dissected recurrent tumor and sacral bone below S2 and preserved S1 nerve roots under direct vision in order to prevent complications such as walking disorder and spinal fluid leakage. The operative time was 870 minutes and the blood loss was 3,600 g. There were no intraoperative complications. Macroscopically, surgical margin was well secured and a pathological examination of resected specimen revealed microfoci of cancer cells. The post operative hospital stay was 36 days. The patient is alive without any evidence of recurrence 72 months after surgery. He has no walking disability, and a good quality of life.
authors.affiliation: Dept. of Gastroenterological Surgery, Osaka University Graduate School of Medicine.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.forename: Masataka
authors.initials: M
authors.lastname: Ikeda
authors.forename: Shinya
authors.initials: S
authors.lastname: Yamashita
authors.forename: Ho Min
authors.initials: HM
authors.lastname: Kim
authors.forename: Hajime
authors.initials: H
authors.lastname: Hirose
authors.forename: Ichiro
authors.initials: I
authors.lastname: Takemasa
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Mizushima
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Sekimoto
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D006801:Humans; D000077146:Irinotecan; D007902:Length of Stay; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011788:Quality of Life; D012004:Rectal Neoplasms / Q000628:therapy*; D012447:Sacrum / Q000601:surgery*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D014803:Vitamin B Complex / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014803:Vitamin B Complex; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D002955:Leucovorin; D002166:Camptothecin